Objectives The purpose of this pilot study was to evaluate the feasibility and safety of transcatheter aortic valve implantation (TAVI) without balloon pre-dilation.
Background Balloon pre-dilation of the stenosed aortic valve is currently believed to be a necessary step for valve preparation before device placement in patients undergoing TAVI and, therefore, is considered an obligatory part of the procedure. However, clear evidence supporting this policy is lacking. In contrast, pre-dilation might be responsible in part for distal embolizations as well as atrioventricular conduction disturbances seen during TAVI procedures.
Methods A total of 60 consecutive patients (mean age 80.1 Ϯ 6.4 years, 53% female, mean logistic EuroScore 23.3 Ϯ 15.2%) undergoing TAVI using the self-expanding Medtronic CoreValve prosthesis (Medtronic, Minneapolis, Minnesota) have been prospectively enrolled at 13 international centers.
Results Pre-procedural mean transaortic valve gradient was 47.8 Ϯ 15.5 mm Hg, mean effective orifice area was 0.67 Ϯ 0.15 cm 2 . Technical success rate was 96.7% (58 of 60) of patients. Post-dilation was performed in 16.7% (10 of 60) of patients. Post-procedural mean valve gradient was 4.4 Ϯ 2.0 mm Hg. Circular and noncircular valve configuration was present in 41 and 19 cases (68.3% vs. 31.7%), respectively, with similar effective orifice areas (1.74 Ϯ 0.10 cm 2 vs. 1.71 Ϯ 0.22 cm 2 , p ϭ NS). Inhospital mortality, myocardial infarction, stroke, and major vascular complications occurred in 6.7% (4 of 60), 0%, 5%, and 10% of patients. There was no valve embolization. New permanent pacing was needed in 11.7% (7 of 60) of patients.
Conclusions Transcatheter aortic valve implantation without balloon pre-dilation is feasible and safe, resulting in similar acute safety and efficacy as the current standard approach of TAVI with pre-dilation. Transcatheter aortic valve implantation (TAVI) has evolved rapidly with an exponential growth of procedures performed worldwide. Today, there is strong evidence that this technology is highly effective in patients with symptomatic severe aortic valve stenosis and high surgical risk (1) . Compared with the very first experiences published in this field (2-7), the technology has developed remarkably over time, with new device generations, reduction of profile sizes, and new access routes allowing for safer and more efficacious procedures in an expanding field of indications.
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Technical success rates up to 97% are now reported (8 -14) , and the incidence of procedure-specific complications is relatively low, given the high comorbid characteristics of the currently treated patient population. However, the most frequent complications are atrioventricular conduction disturbances requiring permanent pacing, access site complications, paravalvular regurgitations, and cerebrovascular events. Particularly, the incidence of strokes due to embolization of fragments liberated from the fragile surface of a degenerated stenosed valve, as well as conduction disturbances due to the close proximity of the aortic annulus and the adjacent left ventricular outflow tract to the conduction system, are known complications that have been reported in surgical series and are more or less linked to manipulations within the degenerated native aortic valve at the various steps of the procedure.
From the very beginning of the TAVI technology, valve preparation by performing a balloon valvuloplasty before the actual device placement has been considered a mandatory step in a TAVI procedure to facilitate the implantation of the prosthesis and reduce the radial counterforce to ensure optimal device expansion. However, evidence supporting this policy is lacking. Instead, balloon valvuloplasty, which alone has been an established palliative procedure for patients with aortic stenosis for more than 2 decades, carries a specific complication risk (15) (16) (17) and can be responsible by itself for distal embolizations resulting in strokes, conduction disturbances, and severe aortic regurgitation with hemodynamic relevance. Therefore, we conducted a multicenter pilot study to assess feasibility and safety of TAVI without balloon pre-dilation.
Methods
Study design. We conducted a prospective pilot study between 2009 and 2010, including 15 international heart centers performing TAVI procedures using the selfexpanding 18-F Medtronic CoreValve prosthesis (Medtronic, Minneapolis, Minnesota). The objective was to demonstrate the feasibility of TAVI without balloon pre-dilation, based on technical success and hemodynamic results compared with the current standard approach of TAVI with predilation. Because the study was designed as a pilot trial, there was no prospective randomized control group. However, we retrospectively compared the results with the Safety and Efficacy 18-F CoreValve study population, recently published by our group (18) .
Clinical and echocardiographic evaluation was performed at baseline and after the procedure at hospital discharge and/or 30-day follow-up. In addition, all patients underwent pre-procedural computed tomography screening, which was used to quantify valve calcification.
Patient inclusion criteria were defined as presence of severe aortic stenosis (0.6 cm 2 /m 2 ), aortic annulus diameter ranging from 20 to 27 mm as determined by echocardiography, ascending aorta diameter Յ45 mm 30 mm above the annulus, age Ն75 years or surgical risk with logistic EuroScore (European System for Cardiac Operative Risk Evaluation) Ն15, or 1 to 2 high-risk comorbidities such as cirrhosis of the liver, pulmonary insufficiency (forced expiratory volume in 1 s Ͻ1 l), previous cardiac surgery, pulmonary hypertension (systolic pulmonary pressure Ͼ60 mm Hg), porcelain aorta, right ventricular failure, or history of mediastinal radiation therapy. All patients provided written informed consent before the procedure. Device and procedure. Design characteristics of the CoreValve prosthesis as well as the procedural characteristics have been described elsewhere (7, 8) . Briefly, the current 18-F generation of the CoreValve prosthesis consists of a trileaflet bioprosthetic porcine pericardial tissue valve, which is mounted and sutured in a self-expanding nitinol stent frame. The device is implanted retrogradely. The currently commercially available third-generation device analyzed in this study is offered in 2 different sizes (26 mm and 29 mm prostheses) for different annulus dimensions ranging from 20 to 27 mm.
All patients underwent the standard TAVI screening procedures including echocardiography and computed tomography as previously described, to assess dimensions and morphologies of the aortic valve, the left ventricle, the aorta as well as the peripheral access vessels. After gaining vascular access and placement of a temporary pacemaker, the left ventricle was entered with a hydrophilic wire, and 2 pigtail catheters were placed in the ventricle and in the ascending aorta, followed by simultaneous pressure measurements and gradient calculations. After placing a manually shaped, stiff guidewire in the ventricle and replacing the pigtail catheter, the prosthesis was advanced over the aortic arch and placed within the diseased native valve. Inability to advance the prosthesis up to the final position within the native valve was considered a device failure. The prosthesis Grube et al. TAVI Without Balloon Pre-Dilation was then implanted within the native valve followed by repeated invasive hemodynamic gradient assessments as well as angiographic assessment of paravalvular regurgitation. In case of significant paravalvular regurgitation (Ͼ2ϩ), postdilation, implantation of a second device or conversion to surgery was considered. Definitions. In accordance with the recently published Valve Academic Research Consortium definitions (19) , technical success was defined as successful vascular access, delivery, and deployment of the device with finally successful retrieval of the delivery system; and correct position of the device in the proper anatomical location with adequate performance of the prosthetic heart valve (mean pressure gradient Ͻ20 mm Hg) and without use of multiple prostheses. Myocardial infarction was defined as elevation of creatine kinase twice the upper limit of normal with the presence of elevated creatine kinase-myocardial band above the upper limit of normal with electrocardiographic evidence of ischemia and a compatible clinical history. Stroke was defined as a new, prolonged (Ͼ24 h) or permanent neurological deficit. Statistical analysis. Categorical variables are presented as frequencies and percentages. Continuous variables are presented as mean Ϯ SD.
Results
A total of 60 consecutive patients (mean age: 80.1 Ϯ 6.4 years, 53% female, mean logistic EuroScore: 23.3 Ϯ 15.2%) undergoing TAVI using the self-expanding 18-F Medtronic CoreValve prosthesis have been enrolled in this pilot study. Indication for TAVI was a symptomatic aortic valve stenosis in all patients (transvalvular gradient from 47.8 Ϯ 15.5 mm Hg). The historic control group consisted of 126 patients (mean age: 81.9 Ϯ 6.4 years, 57% female, mean logistic EuroScore: 23.4 Ϯ 13.8%) who underwent the same procedure using the 18-F CoreValve device (Table 1) .
Technical success rate was 96.7% (58 of 60) of patients in the study population compared with 81.7% in the control group. In 2 patients, the prosthesis was implanted too high, with subsequent implantation of a second device after retraction of the first one into the ascending and descending aorta, respectively. This resulted in a good hemodynamic result in 1 patient; the other patient had to be converted to surgery with explantation of both devices but died shortly thereafter. Post-dilation was performed in 16.7% (10 of 60) of patients in the study population. An example of a successfully implanted prosthesis without pre-dilation is shown in Figure 1 . There was no valve embolization in either group. New permanent pacing was needed in 11.7% (7 of 60) of patients in the pilot study population compared with 27.8% in the control (Tables 2 and 3) . (Fig. 2) 2 , p ϭ NS). Aortic regurgitation of any kind was present in 82% and 58% of study and control patients at baseline, respectively, compared with 58% and 41% after the procedure. There was severe aortic regurgitation (3ϩ) at baseline in 2% of patients of the study population, but there was no severe regurgitation in any group after the procedure (Fig. 3) . Initial degree of calcification of the aortic valve has been judged by echocardiography and/or computed tomography to be severe in 25 cases (41.7%), moderate in 35 cases (58.3%), and mild in 2 cases (3.3%). Major adverse cardiac and cerebrovascular events. Follow-up availability was 100% in the pilot study population and 99.2% (125 of 126) of patients at 30 days in the control group. All-cause mortality up to 30 days was 6.7% versus 14.3% in the pilot study and the control group, respectively. A total of 4 patients died in the study group: 1 patient after unsuccessful placement of 2 devices and subsequent need for conversion to surgery (day 1), 1 patient due to worsening right heart failure on day 3, and 2 patients due to pneumonia and septicemia on day 10 and 13, respectively. Myocardial infarction, stroke, and vascular complications occurred in 0%, 5%, and 10% of patients in the study group as compared with 5.6%, 11.9%, and 9.5% of patients in the control group.
Discussion
This pilot study provides the first evidence that balloon valvuloplasty for pre-dilation of the stenosed aortic valve in patients undergoing TAVI could be omitted due to lack of relevant beneficial procedural effects. Since the first transcatheter aortic heart valve implantation, balloon valvuloplasty has been considered a mandatory step of the procedure for theoretical reasons to "prepare the grounds," given the nature of both the degenerated valve as well the TAVI procedure. Degenerative aortic valve stenosis, the leading cause of aortic stenosis in the elderly, is considered a form of atherosclerosis with mild to heavy calcifications such as active bone formation on the aortic leaflet side of up to all 3 cusps. In addition, this process, as well as inflammation, rarely causes fusion of the commissures resulting in functionally bi-or even monocuspid valves. The technique of aortic balloon valvuloplasty, adopted from valvuloplasties for treatment of pulmonary stenosis, recoarctation, and mitral stenosis, has been a palliative method for more than 2 decades with promising initial (20) and short-term results, but analysis of larger populations has demonstrated poor long-term outcome with high recurrence rates (21) . The acute effects of balloon valvuloplasty on the aortic valve apparatus are only poorly understood, but include fracturing calcified nodules, separating fused commissures, and stretching of the aortic valve ring, all resulting in acute gain of the effective aortic orifice area. Because only microfractures are usually achieved, the rate of restenosis remains high within the first months after intervention, and the procedure is limited by a considerable periprocedural mortality and morbidity with risk of strokes, severe conduction disturbances, severe aortic regurgitation, and decompensation. The acute theoretical effects on the valve apparatus, including the acute orifice gain, were the justification and rationale to implement pre-dilation in the TAVI procedure as a preparatory step just before implantation of the prosthesis, to facilitate the introduction of the device within the diseased aortic valve and to enable an optimized expansion by possibly reducing radial counterforces.
Our pilot study, performing TAVI without balloon pre-dilation, demonstrates the feasibility of this new approach, which might have the potential to facilitate the procedural steps of TAVI. Without pre-dilation, the technical success rate in our study population, defined as successful placement of the device within the stenosed native valve and successful implantation without significant remaining gradient, is higher than the success rate in the chosen control population, which still reflects the early experience with this technology, and is as high as in more recently enrolled patient populations in experienced sites, which report rates of 90% to 97% (8 -14) . Partially respon- Values are % (n).
NA ϭ not available. All-cause mortality 6.7% (4) 14.3% (18) Myocardial infarction 0 5.6% (7) Stroke/TIA 5.0% (3) 11.9% (15) Need for pacemaker implantation 11.7% (7) 27.8% (35) sible for this high technical success rate observed in our study, demonstrating the ease of placing the prosthesis within the native valve, is certainly the relatively low device profile of 18-F, which facilitates the insertion of the device in the stenosed valve. Equally important, we could demonstrate that acute hemodynamic effects are almost identical in patients undergoing TAVI without and with pre-dilation (Fig. 2) . There is no risk of higher residual gradients in patients without pre-dilation, which could have been a concern due to the lack of "preparing" the native valve. The same holds true for the risk of paravalvular regurgitation after device placement, which is not accentuated in the pilot study population compared with the control. Noncircular valve expansion was detectable in 32% of patients, but this did not affect the orifice area or hemodynamics. Because little is known so far on geometry of TAVI prostheses in general, further studies are certainly needed to gather more information on this topic, particularly with regard to incidence and long-term effects of relevant noncircular expansion.
The radial force provided by the TAVI device itself-the CoreValve prosthesis in this case-is obviously sufficient to guarantee a good expansion in most cases. In case of underexpansion, post-dilation can be easily performed, but the need for post-dilation, around 17% in our series, is comparable to other reports (8) and does not indicate a higher rate associated with this new strategy.
Given the low number of enrolled patients, it is difficult to draw meaningful conclusions from the clinical event rates, but the results with regard to mortality, strokes, and myocardial infarction compare favorably with the control group as well as with recently published trials (11) (12) (13) (14) . The need for permanent pacing in only 12% of patients is particularly promising compared with other studies using the CoreValve device (9, 11, 18) . Finally, temporary, highfrequency ventricular pacing, which is usually performed during balloon valvuloplasty to create a functional stand-still of the heart, is not needed during a TAVI procedure without pre-dilation using the CoreValve technology, which implies at least some theoretical benefits, particularly in patients with heart failure and/or severe reduced ejection fraction.
Given the results of this pilot study, TAVI without balloon pre-dilation seems to be feasible and should be investigated further in larger trials, including randomized studies, as this strategy presents an additional attractive facilitation of the procedure, with potential safety benefits. Study limitations. The study enrolled only a limited number of patients. In addition, the historic control group reported in this paper is not equivalent to a randomized or matched control, which needs to be considered when comparing the results of both study populations. Since the control group reflects the early experience with the 18-F CoreValve prosthesis, the results might be affected by learning curve issues. Therefore, larger and randomized trials are needed to provide more insights into this new approach and its value compared with the established techniques. Whether the findings reported in this paper are applicable to a balloonexpandable TAVI technology is unknown so far and must be evaluated in a specific trial. Peak pressure gradients by transthoracic echocardiography pre-and postdilation (A), mean pressure gradients pre-and post-dilation (B), and effective orifice area pre-and post-dilation (C), demonstrating equivalent changes in both the study and control populations.
Conclusions
TAVI without balloon pre-dilation is feasible and safe, resulting in similar acute safety and efficacy as the current standard approach of TAVI with pre-dilation.
